Copyright
©The Author(s) 2020.
World J Transplant. Feb 28, 2020; 10(2): 29-46
Published online Feb 28, 2020. doi: 10.5500/wjt.v10.i2.29
Published online Feb 28, 2020. doi: 10.5500/wjt.v10.i2.29
Figure 2 Incidence of post-transplant lymphoproliferative disorders after allogenic hematopoietic stem-cell transplant.
An additional risk factor in hematopoietic stem-cell transplantation is: recipient age of > 50 yr[4]. HSCT: Haplo-identical allogeneic hematopoietic stem-cell transplant.
- Citation: Abbas F, El Kossi M, Shaheen IS, Sharma A, Halawa A. Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches. World J Transplant 2020; 10(2): 29-46
- URL: https://www.wjgnet.com/2220-3230/full/v10/i2/29.htm
- DOI: https://dx.doi.org/10.5500/wjt.v10.i2.29